Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.46 +0.48 (+1.00%)
Streaming Delayed Price Updated: 11:38 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
31 32 Next >
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
Reuters 
Via Benzinga
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge... 
Via Benzinga
Jupiter Wellness Believes Its Latest Strategic Acquisition Could Be A Significant Boon To Compete In The Medical Cannabis Industry
Companies like Tilray Inc. (NASDAQ: TLRY) and Cara Therapeutics Inc. 
Via Benzinga
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
The U.S. 
Via Benzinga
Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes
Today has been another strong one for investors in Clovis Oncology and CLVS stock, with this company surging another 20% in today's session. 
Via InvestorPlace
Clovis Oncology (CLVS) Stock Rallies on Buyout Rumors
Pharmaceutical startup CLVS stock is climbing 25% higher today on rumors that the cancer drug maker has become a takeover target. 
Via InvestorPlace
Morning Brief: Top Financial Stories Dominating on Monday, June 13
CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here’s Why 
Via Benzinga
Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern
Via Benzinga
We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit
The conversation around obesity is changing. Two diabetes drug makers are at the forefront. 
Via Investor's Business Daily
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
Via AB Newswire
Exposures Product Safety
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children
The U.S. 
Via Benzinga
CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment
Key Takeaways: CStone brought four products to market last year, and its losses have surged due to growing R&D and sales spending Appointment of chairman with close ties... 
Via Benzinga
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Exposures Product Safety
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer
Regeneron secured the global rights to Sanofi-partnered Libtayo. 
Via Investor's Business Daily
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood... 
Via FinancialNewsMedia
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc. 
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Penny Stocks With 10x Potential This Year
These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward. 
Via InvestorPlace
Sanofi To Pay €400K As Compensation For Epilepsy Drug-Related Side Effects
A French court has ordered Sanofi SA (NASDAQ: SNY) to pay more than €400,000 in damages to a French family whose child had autism caused by its epilepsy drug Valproate. 
Via Benzinga
Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients
Via Benzinga
Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
Arkansas has accused Eli Lilly And Co (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and three of the largest pharmacy benefit... 
Via Benzinga
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
The race is on in eczema treatment as the biggest name faces new rivals. 
Via Investor's Business Daily
Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
The story around psychedelic medicine continues to get bigger. 
Via Talk Markets
Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)
Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it’s Q1 report. Some of it’s shortfall was attributed by management to longer sales cycles in the insurer and employer space... 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.